EU/3/18/2100: Orphan designation for the treatment of focal segmental glomerulosclerosis
Table of contents
On 19 November 2018, orphan designation (EU/3/18/2100) was granted by the European Commission to Quality Regulatory Clinical Ireland Limited, Ireland, for propagermanium for the treatment of focal segmental glomerulosclerosis.
The sponsorship was transferred to Raremoon Consulting Esp S.L., Spain in June 2020.
Treatment of focal segmental glomerulosclerosis
|Orphan designation status||
|EU designation number||
|Date of designation||
Scendea (NL) B.V.
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
|January 2023||The sponsorship was transferred from Raremoon Consulting Esp S.L., Spain to Scendea (NL) B.V., The Netherlands|
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: